Exelixis Partner Ipsen Gets Positive CHMP Opinion for CABOMETYX inThyroid Cancer

– CHMP recommendation follows September 2021 U.S. FDA approval of CABOMETYX in this setting –

Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced or metastatic differentiated thyroid carcinoma (DTC), refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy. The European Commission, which has the authority to approve medicines for the European Union, will now review the CHMP recommendation, and a final decision on the application is expected in the coming months. 

https://finance.yahoo.com/news/exelixis-partner-ipsen-receives-positive-124900969.html